Sysmex and Epigenomics AG Announce Strategic R&D Collaboration in Colorectal Cancer Diagnostics
Parties entered into negotiations for a non-exclusive IVD license to mSEPT9 colorectal cancer blood test
Sysmex Corporation and Epigenomics AG announced that they have signed a strategic research and development collaboration agreement in molecular diagnostics. Under the terms of the agreement, Sysmex and Epigenomics will assess the suitability of Sysmex' molecular diagnostics instrumentation for the detection of DNA methylation cancer biomarkers in blood. As a benchmark for the development of its assay system, Sysmex will use Epigenomics' mSEPT9 Methylation Detection Assay commercially available as a research use only product. If successful, Sysmex intends to develop and commercialize initially in Japan a blood test for the early detection of colorectal cancer based on Epigenomics' proprietary SEPT9 DNA Methylation Biomarker (mSEPT9). Upon entering into this collaboration both parties have started negotiations for a non-exclusive mSEPT9 licensing agreement.
Under the terms of the collaboration agreement, Sysmex gets access to Epigenomics' technologies through R&D licenses and technology transfer and will be supported by Epigenomics in its R&D work. In return, Epigenomics will receive certain license fees, R&D funding and reimbursements and will sell its mSEPT9 research use only product to Sysmex.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Genentech to set up Singapore's first Microbial-Based Biopharmaceutical Manufacturing Facility - Fourth Biologics Facility in Less Than 2 Years Helps Establish Singapore as a Serious Player in Biologics Manufacturing
Arakis completes Phase I trials of AD 337 in fibromyalgia syndrome
ABRAXANE meets primary endpoint in phase 3 trial for advanced non-small cell lung cancer
Oncolytics Biotech Inc. has been granted patent for extracting virus from cell culture
Researchers identify genes linked to chemoresistance
